BG
CLDX icon

BlackRock Group’s Celldex Therapeutics CLDX Stock Holding History

BlackRock Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$265K Buy
4,976
+275
+6% +$15.6K ﹤0.01% 2578
2016
Q3 		$286K Buy
4,701
+117
+3% +$7.29K ﹤0.01% 2502
2016
Q2 		$302K Sell
4,584
-563
-11% -$35.7K ﹤0.01% 2435
2016
Q1 		$292K Buy
5,147
+215
+4% +$24.2K ﹤0.01% 2447
2015
Q4 		$1.16M Sell
4,932
-473
-9% -$103K ﹤0.01% 1800
2015
Q3 		$854K Buy
5,405
+994
+23% +$281K ﹤0.01% 1975
2015
Q2 		$1.67M Buy
4,411
+980
+29% +$389K ﹤0.01% 1654
2015
Q1 		$1.43M Buy
3,431
+959
+39% +$343K ﹤0.01% 1655
2014
Q4 		$677K Buy
2,472
+92
+4% +$22.9K ﹤0.01% 2106
2014
Q3 		$463K Sell
2,380
-27
-1% -$5.88K ﹤0.01% 2199
2014
Q2 		$589K Sell
2,407
-1,362
-36% -$308K ﹤0.01% 2134
2014
Q1 		$999K Buy
3,769
+1,304
+53% +$499K ﹤0.01% 1985
2013
Q4 		$896K Sell
2,465
-17,600
-88% -$6.78M ﹤0.01% 2017
2013
Q3 		$10.7M Sell
20,065
-4,305
-18% -$1.48M 0.01% 913
2013
Q2 		$5.71M Buy
+24,370
New +$4.8M ﹤0.01% 962

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock Group's CLDX Position: Q4 2016 in Review

BlackRock Group increased its Celldex Therapeutics (CLDX) stake by 5.8% in Q4 2016, buying an estimated $15.6K and bringing the position to 4,976 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2578.

BlackRock Group first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $10.7M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • BlackRock Group held 4,976 shares of Celldex Therapeutics worth $265K as of Q4 2016.
  • BlackRock Group bought 275 Celldex Therapeutics shares in Q4 2016, an estimated $15.6K.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2578 holding.
  • BlackRock Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Celldex Therapeutics position peaked at $10.7M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.